The cannabis and psychedelics markets in Canada have moved from prohibition to regulation, creating new cross-sector opportunities.
To maximize opportunities for business growth and drive innovation in an increasingly competitive market, it's key to have advisors and advocates who can help you navigate the cannabis and psychedelics industries' unique business, regulatory and legal challenges.
As Canada's Law Firm, BLG has one of the largest cannabis and psychedelics-focused multi-disciplinary legal teams in the country. Our expertise in the industries' complex scientific, regulatory, financial and intellectual property factors are invaluable to our clients.
We have been instrumental in the most high profile and ground-breaking deals and decisions made on the TSX. We also manage complex corporate transactions and advise on operational issues and technology development.
Our cannabis specialists advise cultivators, processors, retailers and everyone in between or adjacent, domestic and foreign, including companies operating in:
- beverage alcohol and other food
- venture capital firms
- investment dealers
- analytical testing
We also advise entities that are not participating in the cannabis industry, including employers (safety-sensitive and otherwise), assisted living facilities, sports and recreation centres, and First Nations and others on preparing policies and regulations to mitigate risks introduced by both medical and adult-use cannabis.
Psychedelics—controlled substances that include psilocybin and MDMA—hold significant promise for a number of applications, including end-of-life depression, treatment-resistant depression, PTSD, eating disorders and substance use disorder.
Our psychedelics specialists are leading advisors for a wide range of stakeholders, including:
- clinical trial sponsors
- product developers and other innovators
- financial institutions
We also support key pro bono efforts to increase access to psilocybin, MDMA and other psychedelics.